PHC-HOLDINGS-CORPORATION
1.4.2019 10:02:10 CEST | Business Wire | Press release
PHC Holdings Corporation (headquarters: Minato-ku Tokyo, Japan, hereafter PHCHD) has today announced that Michael Kloss has taken up the position of President and CEO of PHCHD effective April 1, 2019. Michael succeeds Hidehito Kotani, who has today stepped down as President and CEO.
With more than 20-years of experience in the healthcare industry, Michael Kloss joined PHCHD in 2016 following the acquisition of diabetes care business from Bayer AG and became President and CEO of the newly founded Ascensia Diabetes Care Holdings AG. He has led the diabetes care business throughout the sale from Bayer and has helped to establish Ascensia as a leading diabetes care solutions company.
At an inauguration speech at PHCHD in Tokyo today, Michael Kloss officially stated, “As I take over this role as CEO of PHCHD, we are entering an immensely exciting time for the company. Our ambition is to build a healthcare company with leading global businesses in diabetes care, diagnostics and life sciences alongside a strong healthcare solutions business in Japan. We will achieve this by growing our existing business segments and identifying new ways to expand our products and services. This will enable us to successfully deliver on our mission to contribute to the wellbeing of society by providing solutions for people who wish for better health.”
Michael explained, “The journey for PHCHD started in 2014, when our business carved out from Panasonic group and we set up a Panasonic Healthcare. Since then we have acquired the diabetes care business from Bayer to establish Ascensia Diabetes Care, experienced steady growth across our business segments, and changed our name to PHC Holdings. We are now about to move into the next transformative phase in the development of our company with the proposed addition of the Anatomical Pathology business from Thermo Fisher. Through this potential acquisition, we are adding a new and highly successful business that is showing considerable growth.”
PHC Holdings currently offers value-added products and services through three core businesses: Medical Devices, Life Sciences and Healthcare IT. In January 2019, PHCHD announced the signing of an agreement to acquire the Anatomical Pathology business from Thermo Fisher.
Michael added, “I am thrilled and honored to be taking over this role leading PHCHD and look forward to working with our highly talented employees to successfully grow our business. We have a world-class portfolio of state-of-the-art products and an innovative pipeline of new solutions that can address the unmet needs in healthcare. Our priority is to continue to deliver new value to our customers that will help to build a future of better healthcare for people across the world.”
About PHC Holdings Corporation
Incorporated in 2014, PHC Holdings Corporation is a global healthcare company. Its subsidiaries include PHC Corporation and Ascensia Diabetes Care Holdings AG. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts by creating new value propositions for all the people who wish for better health,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes care, diagnostics, life sciences and healthcare IT. PHC Holdings Corporation group’s consolidated net sales in FY2017 was 192.6 billion yen with global distribution of products and services for more than 125 countries.
For further information on PHC Holdings Corporation, please visit www.phchd.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005284/en/
Contact:
Corporate Communications Group PHC Holdings Corporation Masayo Okada, +81-3-6778-5311
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom